Debanjana Chatterjee
Stock Analyst at Jones Trading
(3.65)
# 868
Out of 5,093 analysts
13
Total ratings
81.82%
Success rate
19.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debanjana Chatterjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics | Upgrades: Buy | $64 | $33.68 | +90.02% | 2 | Dec 1, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Hold | n/a | $9.30 | - | 2 | Nov 11, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $46 | $41.59 | +10.60% | 1 | Sep 8, 2025 | |
| TBPH Theravance Biopharma | Initiates: Buy | $24 | $17.81 | +34.76% | 1 | Jun 17, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $15 → $27 | $6.28 | +329.94% | 2 | Jun 6, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Buy | $39 | $4.29 | +809.09% | 1 | Apr 28, 2025 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | $30 | $16.16 | +85.64% | 2 | Mar 26, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Buy | $23 | $12.50 | +84.00% | 1 | Mar 13, 2025 | |
| PHVS Pharvaris | Initiates: Buy | $46 | $24.04 | +91.35% | 1 | Sep 19, 2024 |
Spyre Therapeutics
Dec 1, 2025
Upgrades: Buy
Price Target: $64
Current: $33.68
Upside: +90.02%
Intellia Therapeutics
Nov 11, 2025
Downgrades: Hold
Price Target: n/a
Current: $9.30
Upside: -
Sionna Therapeutics
Sep 8, 2025
Initiates: Buy
Price Target: $46
Current: $41.59
Upside: +10.60%
Theravance Biopharma
Jun 17, 2025
Initiates: Buy
Price Target: $24
Current: $17.81
Upside: +34.76%
Sagimet Biosciences
Jun 6, 2025
Maintains: Buy
Price Target: $15 → $27
Current: $6.28
Upside: +329.94%
Tvardi Therapeutics
Apr 28, 2025
Initiates: Buy
Price Target: $39
Current: $4.29
Upside: +809.09%
KalVista Pharmaceuticals
Mar 26, 2025
Maintains: Buy
Price Target: $30
Current: $16.16
Upside: +85.64%
Contineum Therapeutics
Mar 13, 2025
Initiates: Buy
Price Target: $23
Current: $12.50
Upside: +84.00%
Pharvaris
Sep 19, 2024
Initiates: Buy
Price Target: $46
Current: $24.04
Upside: +91.35%